ImmuPharma : FDA confirms Type-C meeting date of 7th June 20

FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus

20th April 2023 - 10:20 am

ImmuPharma PLC , the specialist drug... | April 20, 2023

Related Keywords

Tim Mccarthy , Drug Administration , Immupharma Plc Stock Exchange , News , Information , Press Release , Fda , Onfirms , Meeting , Gate , F , Ith , Pune , 023 , Or , Hase , Adaptive , Study , N , 0th , Pril , Immupharma , Lc , The , Pecialist Imm Gb0033711010 ,